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Knowledge Management in the Pharmaceutical Industry 
Between Academic Research and Industry Regulations 
Abstract 
The pharmaceutical sector is one of the pillars of the world’s economy. A significant 
proportion of its value lies in intellectual assets generated through continuous innovation and 
lengthy development cycles within a strictly regulated environment. The purpose of this 
paper is to address the gap between knowledge management (KM) as an expanding academic 
discipline in the pharmaceutical industry and at the same time a growing regulatory 
expectation. A systematic review of 137 refereed KM articles revealed six empirical research 
themes in the pharmaceutical industry. In a subsequent step, the discovered themes and 
subthemes were compared with the extant regulatory expectations as explained in 128 
regulatory guidelines. Findings shed the light on the gap between academic KM research and 
the current thinking of regulatory bodies. Some regulated knowledge processes were 
underrepresented in academic literature. The paper offers also novel insights and 
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1. Introduction 
The acknowledgement of knowledge as a pivotal strategic resource in the current smart 
economy has impelled considerable organisational change. This progressive movement by 
individuals and organizations to manage their intellectual assets developed into KM 
(Davenport & Völpel, 2001). The Pharmaceutical industry is not an exception to this trend, 
not only as a knowledge-intensive industry but also as a leading economic partner with 
transcendent investments in innovation and research. According to European Federation of 
Pharmaceutical Industries and Associations (EFPIA), The Pharmaceutical industry employs 
more than 750,000 employees in Europe, 16% of them working in Pharmaceutical Research 
and Development (R&D) (EFPIA, 2018). 
It is not strange that the significance of KM is also realized by major pharmaceutical 
regulatory authorities. International Council for Harmonisation (ICH) recommends 
management of drug and process knowledge from development and up to product 
discontinuation as an enabler of effective quality management systems. From this 
perspective, KM creates the basis for the manufacturing process, control strategy and 
ongoing continual improvement (ICH, 2009). On the other hand, there are some signs of 
regulatory immaturity of KM. The term “knowledge” is relatively new in regulatory 
publications and is routinely replaced by indirect words such as “science” or 
“product/process understanding” (Calnan et al., 2018). Moreover, KM is seen by ICH only 
as an enabler of The Pharmaceutical quality system (ICH, 2009). 
Thus, as knowledge is another core product of the pharmaceutical industry (Riddell & 
Goodman, 2014), managing stocks and flows of knowledge in this sector emerges as a key 
economic and regulatory objective as well as a growing area of academic research. 
Nonetheless, some knowledge-intensive industries such as pharmaceuticals have not received 
adequate attention in industry-specific publications (Ramy et al., 2017). This paper comes as 
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a comprehensive industry-specific systematic review of KM literature between the academic 
research and regulatory expectations.  
2. Review Methodology 
The high expectations of improving the quality of reviews through well-defined 
methodologies led to the development of systematic review protocols (Jesson et al., 2011). 
Systematic review protocol encompasses specific research questions, the population that is 
the focus of the study, the search strategy and terms for identification of the relevant studies. 
Studies that meet all inclusion criteria and manifest none of the exclusion criteria need to be 
integrated into the review (Davies & Crombie, 1998; Tranfield et al., 2003). The authors 
commenced his review by identifying three research questions: 
Q.1 How is the KM literature in pharmaceutical/biopharmaceutical industry developing? 
Q 2. What are the expectations of regulatory agencies with regard to the identified research 
themes? 
Q 3. What is the future of KM research within the pharmaceutical industry?  
After refining the review questions, the timeframe of review is set to be the last twenty 
years (1996-2016). This time period represents the prosperous period of KM research (Ragab 
and Arisha, 2013a). Furthermore, the timeframe took into account the relative novelty of 
online KM journals. According to Serenko & Bontis (2013) ranking of the KM journals, the 
top-ranked four KM journals (JKM, KMRP, IJKM and JIC) have been published online only 
since 1997, 2003, 2005 and 2000 respectively.  
The criteria for inclusion comprise peer-reviewed electronic business journals in the 
English language retrieved from Emerald Insight and Science Direct database (Table 1). 
Pharmaceuticals related search strings in the titles, keywords or abstracts were used to 
identify the relevant articles. Search strings were synthesised by combining terms like 
“pharmaceutical” or “pharmaceutical industry” with  the most popular KM keywords (such 
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as knowledge sharing, intellectual capital, knowledge transfer or innovation) extracted from 
two comprehensive keyword analysis studies in the KM discipline: Fteimi and Lehner (2016) 
along with Ribière and Walter (2013). After a brainstorming session by the authors, potential 
search strings were approved. The list was updated during the search process. It was meant 
not to tightly plan the review process as this may inhibit researchers’ capacity to explore, 
discover and develop ideas (Tranfield et al., 2003).  
Table 1 Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
KM theories and processes Not related to KM 
With applications in pharmaceutical industry Applied exclusively in other industries 
Peer reviewed journal articles Editorials and position papers  
In English language Articles that use languages other than English 
Published online between 1996 and 2016 From journals that don’t have online domains 
and unpublished work. 
 
After the exclusion of duplicates, Articles that have been retrieved from the search results 
were screened against the inclusion and exclusion criteria by reviewing the titles and 
abstracts (Pati & Lorusso, 2018). A full-text assessment followed where the full-text articles 
were scrutinised to assess relevance to the review questions. The retained articles addressed a 
KM related topic exclusively in the field of pharmaceutical industry or in conjunction with 
other industries.  To mitigate the risk of bias of the reviewed studies (Moher et al., 2015), 141 
eligible articles were quality- assessed at for the clarity of research objectives, adequacy of 
description of the data collection methods and finally the link between data, results and 
conclusion as advised by Kitchenham and Charters (2007). Four articles were excluded at 
this stage due to ambiguous methodology and irrelevance to pharmaceutical industry. 
Ultimately, only 137 articles were retained for analysis after application of 
inclusion/exclusion criteria and quality assessment. A limited number of non-business journal 
papers (e.g. medical journals) and papers identified through cross-referencing and hand 
searching were included (Figure 1).  
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After acknowledgement of main themes and processes in KM literature; the identified 
themes were scrutinised in the regulatory guidelines of five major regulatory bodies. The 
reviewer collected all the published guidelines for pharmaceutical industry on the official 
websites of World Health Organisation (WHO), FDA, ICH, The Pharmaceutical Inspection 
Convention and Pharmaceutical Inspection Co-operation Scheme (jointly referred to as 
PIC/S) and Eudralex- European Union (EU) Legislation. AT the end, 128 guidelines were 
searched for KM related topics in light of the identified themes from academic literature 
review. The analysis was meant to recognise the significance of research themes from 
regulatory perspective as well as the possible research gaps in this field. 
 
Records identified through 
database searching (n=2046) 
Additional records identified 
through other sources (n=18) 
Records after duplicates removed 
(n= 1359) 
Records after titles 
and abstract screening  
(n= 141) 
Records excluded  
(n= 1218) 
Full-text articles 
assessed for eligibility 
and quality (n= 141) 































excluded with reasons 
(n= 4) 
Figure 1 Systematic review process -PRISMA flow diagram (Moher et al., 2015) 




Initially, findings indicate that KM in the Pharmaceutical industry has become a well-
established academic research area. Authorship trends show that approximately 93% of 
articles are published by academic researchers, while the remaining 7% is the product of 
practitioner work. Over the past ten years, a significant increase in collaborative research 
from 62% to 85% is also evident. Among the articles which do specify the function under 
study (approx. 40%), 83% fall within pharmaceutical development and innovation functions 
in contrast to only 8% in production, 4% in sales and 4% in supply chain. In order to identify 
the leading countries in the KM field, the relative contributions of 36 countries whose papers 
were included in this review are traced and ranked using the Equal Credit counting method 
(Chua and Cousins 2002; Lowry et al. 2007). The USA and UK were ranked highest with 
regards to productivity (18% and 11% respectively of all reviewed articles); followed by Iran 
(7%), Australia (7%) and India (6%). It is worth nothing that country contribution in this 
research addresses the country of residence of the author not necessarily where the research 
was held (Figure 2). 
 
Figure 2 Country productivity 
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In terms of methodology, only 29% of the articles adopt literature review as the research 
strategy; while over 70% are empirical studies employing one or more data collection 
methods e.g. surveys (29%), case studies (10%) and interviews (17%). 
Research Themes 
A hybrid method of quantitative keyword analysis and qualitative thematic analysis is 
proposed to identify the common research topics or themes. The most frequent themes and 
keywords (after exclusion of generic keywords e.g. knowledge management, 
pharmaceutical...etc.) are presented in (Table 2). 
Table 2 Themes and Keyword Analysis 
Rank Themes & K. processes Frequency Keywords Frequency 
1 Intellectual Capital 29 Intellectual Capital 27 
2 Innovation 25 Innovation 18 
3 Knowledge Transfer 14 Knowledge Sharing 10 
4 Knowledge Sharing 13 Knowledge Transfer 10 
5 Organisational Performance 12 New Product Development 9 
6 Organisational Culture 12 Research and Development 9 
7 Intellectual Property 10 Intangible Assets 8 
8 Knowledge Creation 9 Organizational Learning 7 
9 New Product Development 6 Organizational Culture 5 
10 Organisational Learning 6 Project Management 5 
 
The identified themes and keywords offer a birds-eye view of the KM landscape. The 
paper presents a classification of KM publications into six areas: knowledge sharing and 
technology transfer, Intellectual Property Protection (IPP), knowledge measurement and 
Intellectual capital (IC) reporting, innovation and knowledge creation (KC), organisational 
knowledge culture and structure as well as Pharmaceutical firm performance (Figure 3). The 
rest of articles fall in miscellaneous category that includes other themes such as: 
organisational learning, knowledge management maturity, data mining, etc. Table 3 presents 
the key articles under each of the featured themes. 
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Figure 3 Literature Map 
 






(Wakefield 2005); (Styhre et al. 2008); (Qureshi and Evans 2015); (Akhavan 
et al. 2015); (Pedroso and Nakano 2009); (Mets 2006); (Lilleoere and 
Hansen 2011); (Lawson and Potter 2012); (Hemmert 2004); (Gray, Roth, 
and Leiblein 2011); (Dooley and Kirk 2007); (Delaney 1999); (Criscuolo 
2005); (Coradi, Heinzen, and Boutellier 2015); (Chávez and Víquez 2015); 
(Brachos et al. 2007); (Bourouni, Noori, and Jafari 2015); (Azan and Huber 
Sutter 2010); (Allen et al. 2016); (Santos 2003); (Mohan, Jain, and Ramesh 
2007); (Malik 2012); (Iwasa and Odagiri 2004); (Filieri et al. 2014); (Chang, 
Yeh, and Yeh 2007); (Buchel et al. 2013); (Bourouni et al. 2015) 
Pharmaceutical 
Firm Performance 
(Mehralian et al. 2012); (Malik 2012); (Kim et al. 2014); (Vishnu and Gupta 
2014); (SubbaNarasimha et al. 2003); (Sharabati et al. 2010); (Pal and 
Soriya 2012); (Kamath 2008); (Garcia Morales, Matias Reche, and 




(Terziovski and Morgan 2006); (Styhre et al., 2002); (Sternitzke 2010); 
(Standing and Kiniti 2011); (Sharma and Goswami 2009); (Roth 2003); 
(Parisi and Hockerts 2008); (Palacios-Marqués, Popa, and Mari 2016); 
(O’Dwyer et al. 2015); (Nightingale 2000); (Mehralian et al. 2014); 
(Lowman et al. 2012); (Lauto and Valentin 2016); (Kneller 2003); (Khemka 
and Gautam 2010); (Kazadi, Lievens, and Mahr 2015); Kale2005; 
Huang2011; Hohberger2016; (Herrmann and Peine 2011); (van 
Geenhuizen and Reyes-Gonzalez 2007); (Gassmann and Reepmeyer 2005); 
(Garcia Morales et al. 2008); (Filieri et al. 2014); (Chen, Jiao, and Zhao 
2008); (Chang et al. 2007); (Cardinal and Hatfield 2000); (Styhre et al. 
2008); (Mets 2006); (Lowman et al. 2012); (Lauto and Valentin 2016); 
(Kazadi et al. 2015); (Gassmann and Reepmeyer 2005); (Cardinal and 




Hatfield 2000); (Boasson and Boasson 2015); (Mohan et al. 2007) 
Intellectual 
Property Protection 
(Yang et al. 2014); (Iwasa and Odagiri 2004); (Boasson and Boasson 2015); 
(Allarakhia and Walsh 2011); (Sternitzke 2010); (Kale and Little 2005); 
(Hohberger 2016); (Chávez and Víquez 2015); (Russell 2016a); (Bollen, 




(Wang, Ashleigh, and Meyer 2006); (Mehralian et al. 2016); (Magnier-
Watanabe and Senoo 2008); (Magnier-Watanabe and Senoo 2010); 
(Magnier-Watanabe, Benton, and Senoo 2011); (Magnier-Watanabe and 
Senoo 2009); (Lindner and Wald 2011); (Guzman 2008); (Evans and Brooks 
2005); (Ebrahimi, Saives, and Holford 2008); (Bigliardi et al. 2012); (Filieri 




(Vishnu and Kumar Gupta 2014); (Tahvanainen and Hermans 2005); 
(SubbaNarasimha, Ahmad, and Mallya 2003); (Singh and Kansal 2011); 
(Sharabati et al. 2010); (Palacios-Marques and Garrigos-Simon 2003); (Pal 
and Soriya 2012); Narula2016; Naidenova2013; (Mehralian et al. 2013); 
(Mehralian et al. 2013); (Kamath 2008); (Huang and Wu 2010); (Hine, 
Helmersson, and Mattsson 2008); (Ghosh and Mondal 2009); (Erickson 
and Rothberg 2009); (Chizari et al. 2016); (Bollen et al. 2005); (Boekestein 
2006); (Boekestein 2009); (Abhayawansa and Azim 2014); (Sydler, 
Haefliger, and Pruksa 2014); (Russell 2016b); (Rossi, Thrassou, and Vrontis 
2015); (Nito 2005); (Mehralian et al. 2012); (Mehralian et al. 2014); (Huang 
et al. 2011); (Boekestein 2009) 
 
Publication years 
The review shows that the majority of included articles have been published between 2004 
and 2016 as shown in (Table 4). 



















































































































1996       1 1 
1997       1 1 
1998       1 1 
1999    1    1 
2000      3 1 4 
2001         




















































































































2002      1 1 2 
2003   2 1 1 2 1 7 
2004 1   2   5 8 
2005 2 1 3 2 1 3 5 17 
2006  1 1 1  2 2 7 
2007    4  3 4 11 
2008  3 2 1 2 4 9 21 
2009  1 4 1  1 3 10 
2010 1 1 2 1 1 2 2 10 
2011 1 2 2 2  3 3 13 
2012  1 2 2 3 2 1 11 
2013   3 1   3 7 
2014 1 1 4 1 2 2 4 15 
2015 2  1 6  4 3 16 
2016 2 1 3 1  4 3 14 
 
3.1. Knowledge Sharing (KS) and Technology Transfer: 
More than 19% of reviewed articles addressed knowledge sharing and transfer signifying 
that Knowledge transfer (KT) holds a special significance in the Pharmaceutical industry. 
Therefore, the WHO dedicates Annex 7 of Technical Report Series no.961 to discuss 
dynamics and controls of technology transfer occurring at some stage in the lifecycle of most 
products in the pharma industry.  However, the real significance of KS comes from the fact 
that it is the component that facilitates continuous knowledge creation (Akhavan et al., 2012) 
and is a key driver of long-term success in a knowledge-intensive organisation (Coradi et al., 
2015). Accordingly, Qureshi and Evans (2015) identify nine categories of deterrents of KS in 
the pharmaceutical organisation. They can be broadly classified as either structural barriers, 
cultural barriers, or managerial barriers.  
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Other studies focused on the attitudes necessary to enhance knowledge sharing (Akhavan 
et al., 2015). Also, Knowledge Networks (KN) are increasingly considered vital channels to 
achieve strategic objectives in project-based organisations particularly Pharma R&D 
(Bourouni et al., 2015). By the same token, structural indexing and knowledge dictionaries 
can identify knowledge agents and evaluate intra-organisational knowledge sharing. 
Enhancing knowledge flow among R&D stages can be crucial to shorten the product to 
market timing (Wakefield, 2005). 
As physical proximity is one of the suggested barriers for Knowledge Sharing and 
Technology Transfer (Lilleoere & Hansen, 2011), several studies handle this topic in pharma 
explicitly. For instance, studies conducted in the R&D department of multinational drug 
manufacturer Novartis reveal that co-location of dispersed project teams leads to faster and 
more precise flow of knowledge (Coradi et al., 2015).  
On a macro scale, an equally significant aspect of inter-organisational KS is geographic 
distribution. Higher quality risk can accompany offshore manufacturing due to challenges of 
KT from headquarters (Gray et al., 2011). Pharmaceutical firm location is found to influence 
the intensity of communication between different firms but not the innovation. Relocation 
(e.g. into industry clusters) and expensive real estate investments can be replaced by 
enhancing the social connections through technology (Allen et al., 2016). In spite of that, 
having an R&D laboratory near corporate headquarter enhances new drug productivity as 
proximity is necessary for the integration of R&D with other functions (Cardinal & Hatfield, 
2000).  
 
3.2. Intellectual Propriety Protection (IPP): 
There is no industry where firms build their competitive advantage more closely to IPP 
than the pharmaceutical industry. However, in response to dramatic transitions in bioscience 
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and computational chemistry, biopharmaceutical companies commence newer approaches for 
managing their IP and innovation including open access, exclusive and non-exclusive 
licensing (Allarakhia & Walsh, 2011). Although the exclusive licensing is more preferred in 
the pharmaceutical industry (2:1), non-exclusive licensing provides a strategic advantage to 
the company and reduces market uncertainty by decreasing competition (Malik, 2012).    
The real significance of IP for the pharmaceutical industry comes from the belief that 
patents are used as a proxy indicator of knowledge creation (Nerkar, 2003). Also, patent 
citations studies in pharma exploit patent-related data to estimate the quality of innovation, 
diffusion of knowledge and geographic localisation of knowledge (Chávez & Víquez, 2015). 
For this reason, patents can affirm firm’s value and market performance. Association 
between company value, reported intangible assets and R&D capitals is proven (Russell, 
2016).  
In a highly dynamic global economy, enforcing IP protection laws implies significant 
costs particularly on developing economies (Mazzoleni & Nelson, 1998). Nevertheless, IPP 
is an important incentive for innovation in advanced countries enjoying both a superior 
technological infrastructure as well as a rich market for new drug (WHO, 2006a).   
3.3. Knowledge Measurement and IC Disclosure: 
Empirical evidence supports the notion that the nature and value of knowledge assets 
differ from industry to another with a direct impact on investment decisions. By using 
Tobin’s Q model for knowledge measurement, it is noticed that not only the level of 
intellectual capital (IC) and competitive intelligence are both higher in consumer industries 
(such as pharmaceuticals) in comparison to business to business industries, but also 
investments in knowledge assets are more promising (Erickson & Rothberg, 2009). 
Measurement of pharmaceutical IC at organisational level relies on the identification of most 
relevant constructs or indicators in each industry (Palacios-Marques & Garrigos-Simon, 
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2003). For example, management experience and technical knowledge are on the top of HC 
indicators in pharma. Regarding structural capital, organisational culture, the ratio of 
investment in R&D and number of R&D projects are the highest priority indicators. 
Additionally, mutual trust with customers and their satisfaction are the highest priority RC 
indicators (Mehralian et al., 2013).  
However, the disclosure of IC in balance sheet (BS) is still a measurement barrier and an 
opportunity for improvement in the pharmaceutical industry, particularly in developing 
countries. The lack of standardized accounting guidelines on this vital asset results in 
unreporting of resources of billions in firm’s annual reports with impact on their performance 
in the stock market (Abhayawansa & Azim, 2014).  
Intellectual capital is widely adopted as a predictor for firm’s profitability in 
pharmaceutical sector (Sydler et al., 2014). Healthcare patents reflect firm’s innovative 
capabilities and enhance the capacity to raise necessary start-up capital (WHO, 2006a). 
However, no significant relationship was observed either between IC and productivity or 
market valuation (Ghosh & Mondal, 2009; Pal & Soriya, 2012). This argument is subject to 
controversy as companies which generate more profits are able to invest more in IC 
(Naidenova & Parshakov, 2013).  
In the pharmaceutical industry, Merger and Acquisition (M&A) is used as cost-effective 
way to gain access to new product platforms, technologies and patents; traditional 
pharmaceutical companies with dried-out research pipelines but sufficient cash  acquire 
innovative biotech firm as a source of new products (Rossi et al., 2015). M&A can be seen as 
an opportunity to overcome the underestimation of intangible assets under current accounting 
systems in pharma companies (Boekestein, 2009). 
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3.4. Research, Innovation and knowledge creation (KC): 
The emergence of new discoveries in the twenty-first century will urge Pharmaceutical 
manufacturing to employ innovation and cutting-edge technology as ways of doing business 
(FDA, 2004b). Nowadays, pharmaceutical industries do not typically fit to the classic 
economy of scales theories as they transformed into R&D intensive rather than production 
intensive (Gassmann & Reepmeyer, 2005). Pharmaceutical industry becomes more than other 
industries dependent on scientific advances, particularly in basic sciences, developed in 
public sector (Sternitzke, 2010). Historically, public sector role in drug discovery was limited 
to basic research to elucidate the basic pathological mechanisms. However, this role has 
significantly expanded in the biotechnology era (Stevens et al., 2011). In contrast with 
publically funded drug research model in EU and US universities, it is noticed that drug 
discovery in Japanese companies occurs predominately in-house which may be no longer 
compatible with global competitiveness (Kneller, 2003).   
In such a complex R&D environment, information sharing and intrinsic motivation are 
recognized as important drivers for organizational creativity (Sundgren et al., 2005). There is 
a significant influence of knowledge transfer on firm innovative capability (r= 0.893) too 
(Palacios-Marqués et al., 2016). As the bulk costs of R&D come from the clinical phases, 
sharing knowledge and experiences coming from terminated projects would be of high 
significance (Styhre et al., 2008).  
Surveyed literature highlights some of the dynamics of innovation within pharma 
organisation. Management support and effective management of knowledge are found 
indispensable if the organisation wants to adopt an innovative environment. Additionally, Job 
satisfaction explains up to 25% of the variance in innovation regression models (Khemka & 
Gautam, 2010). Transformational leadership shows a positive relationship with innovation 
(Garcia Morales et al., 2008). Also, a significant positive relationship is established between 
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organisation capital and innovation confirming the remarkable role of intangible assets in 
generation and enhancement of innovative capabilities (Huang et al., 2011).  
Conversely, outsourcing of R&D and clinical studies for new product development (NPD) 
and the associated knowledge losses as well as regulatory delays create innovation risks 
(Lowman et al., 2012). Likewise, FDA warned from the threats of broad interpretations of 21 
CFR part 11 (electronic records and electronic signatures) on innovation and technological 
advances without any benefit for patient health (FDA, 2003).  
 
3.5. Knowledge Culture and Organisational Structure: 
FDA encourages management to implement quality systems and procedures that support a 
communicative culture. Under such work culture, employee suggestions are appreciated and 
used for continual improvement (FDA, 2006). Along the same line, beliefs and knowledge-
related values (love, care and trust) can be potential sources of competitive advantages in 
pharma (Remy Magnier-Watanabe & Senoo, 2009). 
Knowledge culture is a way of organizational life that empowers people to create, share 
and use knowledge for the good of the organisation (Oliver & Kandadi, 2006). In the 
pharmaceutical industry, knowledge culture is believed to compensate for the lack of 
organisation memory in temporary project teams where information Communication 
Technology (ICT) systems are not enough alone for ensuring the exchange of knowledge 
(Evans & Brooks, 2005; Lindner & Wald, 2011). Organisation memory held by aging 
workers can be transferred to the younger workers through bridges of socialisation and 
adequate organisational climate (Ebrahimi et al., 2008).  
Organisational characteristics of pharmaceutical firm such as structure and strategy affect 
knowledge acquisition activities including knowledge storage, diffusion and application 
(Rémy Magnier-Watanabe & Senoo, 2008). In fact, organisational characteristics can have 
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even more influence over KM than national culture (Rémy Magnier-Watanabe & Senoo, 
2010). For example, open culture where employees can raise questions and feel at ease 
explains 31% of the variance in four modes of SECI process compared to only 16% for 
bureaucratic culture (Rémy Magnier-Watanabe et al., 2011). In pharmaceutical R&D, 
bureaucratic culture has a negative impact on knowledge workers’ job satisfaction while 
innovative or supportive culture positively influences them (Bigliardi et al., 2012).  
3.6. Pharmaceutical Firm Performance: 
Human and Relational Capital is deemed to positively impact business performance of the 
pharmaceutical firm (Sharabati et al., 2010). Several empirical studies have underlined this 
paradigm utilising either return on asset (ROA) as performance measures (Vishnu & Gupta, 
2014); whereas, Value Added Intellectual Coefficient (VAIC) (Chizari et al., 2016) or 
generation of new patents were used as proxies for technical knowledge of firms 
(SubbaNarasimha et al., 2003). Even more striking is the fact that each of the three 
components of IC is not only individually related to firm performance, but also they 
collaborate together in the way they influence firm performance (Bollen et al., 2005). KM 
performance is considered as a predictor of superior financial performance in terms of higher 
profit ratios (ROA, ROS) and lower cost ratios (OPEX) (Holsapple & Wu, 2011).   
KM strategies can influence organisational performance in pharma. Information system 
maturity in the pharmaceutical firm as well as knowledge intensity would be the determinants 
for the most effective KM strategy (Kim et al., 2014). Internal organisational tensions 
between tacit-oriented and explicit-oriented strategies, which are difficult to reconcile, would 
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3.7. Regulatory Insights: 
A through exploration of KM in 128 Good Practice (GxP) quality guidelines (Table 5) has 
revealed a slightly different pattern of interests and expectations in comparison with the 
academic business journals (Figure 4). 
 
Figure 4 Key themes in regulatory guidelines 
 
An overview of the current thinking and expectations of key regulatory bodies regarding 
KM is presented as follow: 
ICH 
 From the previous review sections, KM expresses a considerable level of maturity as an 
academic research field in the pharmaceutical industry. Despite that, KM shows less mature 
roles at industry level which might hinder the achievement of ICH Q10 desired state (Calnan 
et al., 2018). KM received meagre attention by regulatory agencies (Rathore et al., 2017). For 
instance, ICH Q10 considers KM together with QRM as the enablers of its effective 
implementation throughout the product lifecycle. Proper implementation of ICH Q10 
guidelines is deemed necessary for innovation and continual improvement and strengthening 
the link between pharmaceutical development and manufacturing activities. Last but not 
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least, ICH Q10 suggests monitoring of all innovations that might enhance QMS (ICH, 2008). 
Other ICH guidelines refer sporadically to KM with a focus on KS/KT. ICH Q9 suggested 
the need for further studies related to technology transfer should be assessed through QRM 
(ICH, 2005). ICH Q11 endorses the management and sharing of product/process related 
knowledge throughout product lifecycle including knowledge related to drug substance and 
its manufacturing process. This is supposed to enhance the manufacturing process and 
establish a control strategy especially in cases of product ownership changes.  
WHO 
For the purpose of earlier detection of potential problems, WHO guidelines pay close 
attention to regulatory harmonisation and participation in information (e.g. from inspections 
and clinical studies) sharing networks among regulatory agencies with special considerations 
to confidentiality and intellectual property issues (e.g. (WHO, 1999, 2003, 2017). Parallel 
efforts are exerted to contain escalating costs of drug prices by minimizing duplication of 
inspection activities through: better networking, enhanced collaboration, and increased 
mutual trust (WHO, 1999). Information sharing efforts with the European Directorate for the 
Quality of Medicines & Healthcare (EDQM) extends to certification programs (WHO, 1999). 
Risk communication and sharing risk related knowledge are also addressed in WHO 
guidelines (WHO, 2013). Finally yet importantly, sharing public alerts and warning alerts for 
imported drugs or medical devices can prevent similar faulty products from being exported to 
other markets (WHO, 2017). 
WHO identifies the technology transfer as the middle stage in the drug lifecycle where 
GMP regulations must apply (WHO, 2013, 2014). The organisation requires validation of the 
process of data transfer (WHO, 2016). Whenever the transfer involves analytical methods, it 
is required to conduct this validation by the development before transfer to manufacturing 
quality control. Periodic checks are necessary to ensure the accuracy and reliability of the 
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process (WHO, 2006c). As a general requirement, mechanisms should be addressed to 
facilitate the transfer of information not only between manufacturers and customers but also 
to the relevant regulatory bodies (WHO, 2010a). 
With regard to IPP, The International Medical Products Anti-Counterfeiting Taskforce 
(IMPACT) is led by WHO, where the focal point is public health protection from the 
implications of counterfeiting (WHO, 1999). The ever-changing business strategies and their 
accompanying intra- and intercompany transfers of technology obliged the WHO Expert 
Committee on Specifications for Pharmaceutical Preparations in its 42nd report to assign a 
special guideline to address this issue (TRS 961 Annex 7). However, this guideline is meant 
to be a flexible framework rather than rigid technology transfer guidance. Although a 
multifunctional team is proposed to manage the transfer process, it is affirmed to be under the 
umbrella of a quality system (WHO, 2011). 
WHO requires pharmaceutical manufacturers to build their quality decisions and 
regulatory commitments on science-based understanding of the process and QRM which can 
offer a greater freedom of how to comply, hence enhances innovation (WHO, 2013). 
Development of quality culture in the pharmaceutical organisation is believed to improve 
transparency about failures and ensure good data management strategies are in place. 
Besides, data integrity and protection occupied a featured position in WHO regulations. 
Pharmaceutical firms are expected to develop appropriate tools and strategies for the 
management of data integrity risks based upon their own GxP activities, technologies and 
processes (WHO, 2016). 
 
EU GMP 
Furthermore, EU Guidelines for Good Manufacturing Practices (Eudralex) have adopted 
Good Documentation Practices as an enabling tool for knowledge management throughout 
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different stages of product lifecycle (EudraLex, 2015). Similar to WHO, PIC/S and ICH 
recommendations, the guidelines encourage agents, brokers, distributors, repackers or 
relabellers to share regulatory and quality information with the manufacturers and customers 
(Eudralex, 2004; ICH, 2000; PIC/S, 2017; WHO, 2010b). Eudralex requires analytical 
method transfer protocol (Eudralex, 2006) with no explicit transfer framework as in WHO 
TRS961 Annex 7. However, it confirmed the coverage of technology transfer by cGMP 
regulations as a part of product lifecycle (Eudralex, 2011). 
FDA 
FDA pays special attention to process understanding and knowledge management as 
effective strategies for preventing and detecting data integrity issues (FDA, 2016c). On the 
other hand, FDA accentuates on knowledge sharing and transfer in contract manufacturing as 
explained in the quality agreement (FDA, 2016a). The agency highlights the role of senior 
management in the creation of communicative organisational culture as a tool for improving 
knowledge sharing and communication in addition to cross-functional groups to share ideas 
for improvement purposes (FDA, 2006).In addition, FDA encourages data acquisition and 
accumulation over the lifecycle as an important way for continuous improvement which in 
turn can facilitate the scientific communication with the agency (FDA, 2004a). Similarly, 
following process validation FDA guidelines would support process improvement and 
innovation (Services & FDA, 2011). 
PIC/S 
In response to the increasingly complex global supply chains in the pharma industry, 
PIC/S facilitates voluntary inspection data-sharing between member authorities. This is 
deemed to enable risk-based assessment of the need for inspections based on shared 
confidence in inspected firms (PIC/S, 2011b). It has not escaped our notice that data sharing 
and transfer in PIC/S guides is focused on inspection data rather than knowledge created in 
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pharmaceutical firms. The statute of the International Medicinal Inspectorates Database 
(IMID), which aims at establishing a database of GMP inspections carried out by IMID 
participating Regulatory Authorities, was adopted by PIC/S to reduce the number of 
duplicative inspections (PIC/S, 2012). Besides, the PIC/S committee is cooperating with 
other global agencies such as WHO, EMA, the ICMRA (International Coalition of Medicines 
Regulatory Authorities) and United Nations Children's Fund (UNICEF) with regard to 
training and sharing of inspections’ information (PIC/S, 2011a, 2015, 2016b; WHO, 2003). 
Because data integrity is essential for successful implementation of GMP, the 
requirements for good data management are embedded in the current PIC/S guidelines to 
GMP/GDP for Medicinal products. Good data management practices (GDMP) are envisaged 
as fundamental enabler for the integrity of the generated data. The manufacturer or distributor 
undergoing inspection is required to enforce GDMP that ensure the accuracy, completeness 
and reliability of data (PIC/S, 2016a).  
The data lifecycle (from generation till discard at the end of retention period) is also 
featured in GMP guidelines including data transfer throughout the product lifecycle. In case 
of computerised systems, interfaces should be assessed and addressed during computer 
system validation to guarantee the correct, accurate and complete transfer of data (PIC/S, 
2016a, 2017). Risk review should be considered specially for supply chains and outsourced 
activities to assess the extent of data integrity controls required (PIC/S, 2016a). It is 
noteworthy that PIC/S has repeatedly warned of inappropriate interpretation of guidelines 
making them barriers to technical innovation or the pursuit of excellence (e.g.PIC/S, 2011c). 
Organisational culture and behaviour are a complementary part of the effective data 
governance system when combined with an understanding of data criticality, data risk and 
data lifecycle. The value behind this appears in the empowerment of employees to report 
failures and opportunities for improvement. This reduces the incentive to falsify, alter or 
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delete data (PIC/S, 2016a). GMP inspectors have to be sensitive to the effects of 
organisational culture and structure on the organisation behaviour where data reporting 
differs between open and close cultures. In order to ensure data integrity within the 
pharmaceutical organisation, appropriate values, believes, thinking and behaviours need to be 
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4. Discussion and Implications: 1 
The pharmaceutical industry is not only one of the knowledge-intensive sectors, but also 2 
an industry with a direct effect on health promotion (Mehralian et al., 2016). It comprises 3 
distinct characters making pharmaceutical knowledge management a unique process. Being  4 
research-intensive, highly innovative and a great source of IC  (Kamath, 2008), building 5 
networks of R&D personnel with research institutions, providing ultimate protection of IP 6 
rights, having high influence of political, legal and administrative factors on technology 7 
acquisition (Hemmert, 2004),  achieving high level of maturity in project management 8 
(Wakefield, 2005), involving suppliers in product development activities (Lawson & Potter, 9 
2012), involving collaborative research with universities and governments (Dooley & Kirk, 10 
2007), presenting sophisticated drug discovery and development systems (Criscuolo, 2005), 11 
facing challenges of regulated prescription drugs (Pedroso & Nakano, 2009), being one of the 12 
fast growing economic sector (Singh & Kansal, 2011), together with huge economic 13 
productivity and high number of employees (Bigliardi et al., 2012) are some of reasons for 14 
choice of pharmaceutical industry as empirical research field in KM literature.   15 
Based on an in-depth review of the literature, few trends emerge. Domination of academic 16 
authorship (93% of authors) and empirical research (>70%) in 36 countries along with 20% 17 
increase in co-authorship reflects the academic maturity of the research area.  Participation of 18 
practitioners is relatively limited (7%) in spite of the colossal investments in KM by pharma 19 
companies (Riddell & Goodman, 2014). This also validates the notion that the role which 20 
“knowledge” plays in the pharmaceutical industry is still immature and disabling the ICH Q 21 
10 desired pharmaceutical quality system (Calnan et al., 2018). This can also accentuate what 22 
has been described by Ragab and Arisha (2013) as a theory-practice gap in KM literature in 23 
general.  24 
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Since R&D is considered the key space for knowledge creation (Ingelgård et al., 2002; 1 
Parisi et al., 2006), most of the studies ignored other functions (e.g. manufacturing, sales or 2 
quality) or other sources of knowledge in pharmaceutical organisation (e.g. process validation 3 
studies; manufacturing experience, continual improvement, and change management 4 
activities). From a regulatory perspective, managing the knowledge throughout 5 
commercialisation and manufacturing phases until product discontinuation is supposed to be 6 
as important as managing drug development knowledge (ICH, 2009).  7 
Taxonomical analysis of literature affirms six main knowledge processes/ themes 8 
extensively covered by researchers (Figure 3). In spite of that, the research in some other 9 
potential areas is relatively scarce (e.g. knowledge acquisition). In addition, the current 10 
thinking of the pharmaceutical regulatory bodies doesn’t match the trending themes in 11 
business literature. For example, technology transfer and method/process transfer are 12 
regulated practices under pharmaceutical quality systems (ICH, 2009; WHO, 2011); case 13 
studies or empirical research is quite limited in this area.  14 
IC is the most frequently used keyword and research theme in pharmaceutical KM 15 
literature. The influence of pharmaceutical IC on profitability, productivity and market value 16 
is addressed in several papers (e.g. Pal and Soriya, 2012). Pharmaceutical IC reporting in BS 17 
suffers from inconsistency and lack of standardised guidelines. Yet, Intellectual Capital, 18 
knowledge measurement or disclosure are not recognised by cGMP guidelines. While M&A 19 
implications were a subject of academic research in pharma companies, regulatory 20 
publications focus on knowledge transfer after product/process acquisition or data acquisition 21 
during product lifecycle (FDA, 2004a). 22 
Although KM at product and process level is explicitly required in ICH Q10 1.6.1.(ICH, 23 
2008), regulatory authorities didn’t suggest any framework for either measurement or 24 
disclosure of IC. With poor reporting and disclosure of IC in pharma (Abhayawansa & Azim, 25 
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2014), further research is needed to induce industry-specific measurement frameworks not 1 
only at organisational IC level but also at the individual knowledge level. As a part of 2 
company intangible capital, patent-related keywords are mentioned 10 times in the review 3 
pool (e.g. patent citation, analysis, research, count, etc.) reflecting the importance of IP rights 4 
as a research subject.  5 
Governmental role in innovation, either through the outputs of basic science or public 6 
funding of growing industry R&D, is emphasised in the literature. Dynamics of innovation as 7 
managed by the Triple Helix model can be a meticulous explication of this phenomenon 8 
(Etzkowitz & Leydesdorff, 2000; Leydesdorff & Meyer, 2006). When the FDA announced 9 
the Pharmaceutical cGMPs for the Twenty-first Century in 2006; corrective actions, 10 
innovation and continuous improvement were considered as three complementary 11 
improvement approaches in Pharmaceutical Manufacturing (FDA, 2004b). However, only 12 
innovation has received enough attention in the surveyed literature. It is worth nothing that 13 
the term “creation” was mainly used by the regulators to signify creation of data and/or 14 
electronic records (FDA, 2016b). 15 
The review explored the role of pharmaceutical organisational culture and structure in 16 
knowledge management. The review confirmed the notion that some values are found to be 17 
associated with the prosperity of knowledge within workspace (Remy Magnier-Watanabe & 18 
Senoo, 2009) and a new technology is not able alone to bring about a successful KM system 19 
(Chatzkel, 2007). The KM performance of the company was found in general related to its 20 
market performance. Unlike pharmaceutical quality system (ICH, 2008), organisational 21 
performance as a function of its KM practices was not considered by any of the four 22 
regulatory bodies. 23 
 24 
 25 
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5. Conclusion and Limitations of Research: 1 
According to the pharmaceutical regulatory guidelines, personnel must be qualified and 2 
knowledgeable with functions related to their work activities (FDA, 2006; WHO, 2014). It is 3 
a requirement to manage product and process knowledge throughout the product lifecycle 4 
(ICH, 2008). However, the academic research interests in pharmaceutical knowledge as 5 
presented in the extant KM literature partially overlap with the regulatory concerns. This 6 
incomplete overlap offers an opportunity for business researchers to design their future work 7 
to help industry meet regulatory expectations. Regulatory bodies recommended knowledge 8 
management but did not provide comprehensive frameworks to manage knowledge of 9 
pharmaceutical firms at the time industry practitioners refrain from serious contribution to 10 
academic research. This supports the notion that knowledge management in pharmaceuticals 11 
is still a growing research area, particularly in non-research and development functions.  12 
The review has the limitation of being restricted to articles extracted from the Emerald 13 
Insight and Science Direct databases. Knowledge management conference proceeding and 14 
other academic portals can be explored in future studies. Despite the limitations, this paper 15 
offers an integrative and comprehensive taxonomy of KM literature in an industry-specific 16 
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